Sustainability is no longer the road less traveled, and QIAGEN N.V. (QGEN) is showcasing leadership in this arena with two significant achievements. My Green Lab, the non-profit organization dedicated to advancing sustainability in scientific research, has recognized QIAGEN for its outstanding commitment in reducing the environmental impact of its products.
Green Stars for QIAGEN
The prestigious ACT (Accountability, Consistency, and Transparency) Environmental Impact Factor Label was awarded to QIAGEN for the new QIAwave products. The company also achieved My Green Lab Platinum certification for its Sample technologies R&D lab in Germany. These accolades not only signify QIAGEN’s dedication to sustainability but also bolster its Life Sciences business segment.
Revolutionizing the Eco-friendly Product Line
In 2023, QIAGEN expanded its QIAwave product line by introducing the QIAwave RNeasy Plus Mini Kit and the QIAwave DNA/RNA Mini Kit. Designed to use up to 62% less plastic and up to 58% less cardboard, these kits are a sustainable choice for laboratories. My Green Lab found that these new products led to a substantial improvement in the Environmental Impact Factor, further solidifying QIAGEN’s commitment to eco-friendly solutions.
Image Source: Zacks Investment Research
In a notable development, the R&D lab for Sample technologies at QIAGEN’s European operational headquarters in Hilden, Germany, achieved the Platinum certification level from My Green Lab. This recognition reflects the actionable steps taken by QIAGEN to reduce costs, preserve resources, and uphold a safe and healthy environment in support of science. The company is on track to have all its Life Sciences labs at the Hilden site certified by the organization.
Recognitions and Beyond
QIAGEN’s commitment to sustainability has also been acknowledged by other independent rating agencies. ISS-ESG elevated QIAGEN’s rating to B-, reaffirming its “Prime“ status. Moreover, QIAGEN received a grade A from MSCI ESG Research while being placed in the low-risk group by Sustainalytics ESG Risk Ratings. QIAGEN’s emission reduction targets, validated by the Science Based Targets initiative, are directed towards achieving net-zero greenhouse gas emissions by 2050.
In the wake of these recognitions, QIAGEN is empowering its life sciences business through a collaboration with Penn State University to support the development of new products at the “One Health Microbiome Center”, alongside faculty and students.
Market Movement
Despite these achievements, QGEN shares have faced a 4.5% decline in the past six months, in contrast to the industry’s 1.7% rise.
Analyst Recommendations
Although QIAGEN currently carries a Zacks Rank #4 (Sell), industry peers such as Cardinal Health, Stryker and DaVita have been rated favorably. Cardinal Health and Stryker each hold a Zacks Rank #2 (Buy) while DaVita boasts a Zacks Rank #1 (Strong Buy).
The uptrend in Cardinal Health’s stock, with a 32.6% increase in the past year, showcases strong performance and upwardly revised earnings estimates. Similarly, Stryker’s shares have climbed 32.8% and its earnings estimates for 2024 have been revised upward. DaVita has also made positive strides, with a 45.6% increase in its shares in the past year and upwardly revised earnings estimates.
Zacks Names #1 Semiconductor Stock
With a backdrop of volatile market trends, QIAGEN’s sustainability milestones are vital, projecting both environmental consciousness and factory-friendly options. These recognitions underscore the company’s important strides towards environmental sustainability, very much like a marathon runner who pushes past every hurdle laid out. The recognition benchmarks are like medals strung around the company’s neck, earning it the accolades it deserves. The road ahead may be winding, but QIAGEN seems heartsore for the journey.
See This Stock Now for Free >>
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
